Abstract
No standard treatment exists for non-small cell lung cancer (NSCLC) with failure of first-line therapies. Combination of antiangiogenic therapy and immune checkpoint inhibitor therapy is reported as an effective antitumor strategy. Anlotinib is a novel multi-target tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling.We aimed to assess the activity and safety of anlotinib combined with immunotherapy as second-line therapy for advanced NSCLC.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have